Piramal Pharma Limited (PPLPHARMA) Price & Analysis

Compare

9 Followers

PPLPHARMA Stock Chart & Stats

₹192.65

-₹4.80(-1.92%)

At close: Jan 08 4:00 PM EST

₹192.65

-₹4.80(-1.92%)

Day’s Range― - ―

52-Week Range₹169.65 - ₹273.20

Previous CloseN/A

Volume1.66M

Average Volume (3M)263.77K

Market Cap

₹231.95B

Enterprise Value₹293.24B

Total Cash (Recent Filing)₹4.08B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta0.58

Next Earnings

Feb 03, 2026

EPS Estimate

0.2

Next Dividend Ex-DateN/A

Dividend Yield0.08%

Share Statistics

EPS (TTM)-0.70

Shares Outstanding1,329,248,200

10 Day Avg. Volume418,763

30 Day Avg. Volume263,767

Financial Highlights & Ratios

PEG Ratio0.84

Price to Book (P/B)3.72

Price to Sales (P/S)3.30

P/FCF Ratio132.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹305.00

Price Target Upside58.32% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.16

Revenue Forecast (FY)₹91.58B

Piramal Pharma Limited News

Piramal Pharma Completes Major Financial Transaction

An update from Piramal Pharma Limited ( ($IN:PPLPHARMA) ) is now available. Piramal Pharma Limited announced the completion...

4M ago

Piramal Pharma Limited’s 5th AGM: Resolutions Passed and Shareholder Engagement Enhanced

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an update. Piramal Pharma Limited successfully conducted its 5th Annual...

5M ago

Piramal Pharma Receives ESG Rating from NSE Sustainability

An update from Piramal Pharma Limited ( ($IN:PPLPHARMA) ) is now available. Piramal Pharma Limited has been assigned...

5M ago

Piramal Pharma Expands Sevoflurane Production to Tap Global Markets

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has shared an update. Piramal Pharma Limited has commenced commercial production of...

9M ago

Piramal Pharma Appoints New Non-Executive Director

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an announcement. Piramal Pharma Limited announced the approval of a...

9M ago

Piramal Pharma Secures $216 Million Financing with Corporate Guarantee

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an update. Piramal Pharma Limited has issued a corporate guarantee...

11M ago

PPLPHARMA FAQ

What was Piramal Pharma Limited’s price range in the past 12 months?

Piramal Pharma Limited lowest stock price was ₹169.65 and its highest was ₹273.20 in the past 12 months.

What is Piramal Pharma Limited’s market cap?

Piramal Pharma Limited’s market cap is ₹231.95B.

When is Piramal Pharma Limited’s upcoming earnings report date?

Piramal Pharma Limited’s upcoming earnings report date is Feb 03, 2026 which is in 48 days.

How were Piramal Pharma Limited’s earnings last quarter?

Piramal Pharma Limited released its earnings results on Nov 05, 2025. The company reported -₹0.7 earnings per share for the quarter, missing the consensus estimate of -₹0.345 by -₹0.355.

Is Piramal Pharma Limited overvalued?

According to Wall Street analysts Piramal Pharma Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Piramal Pharma Limited pay dividends?

Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here

What is Piramal Pharma Limited’s EPS estimate?

Piramal Pharma Limited’s EPS estimate is 0.2.

How many shares outstanding does Piramal Pharma Limited have?

Piramal Pharma Limited has 1,329,248,200 shares outstanding.

What happened to Piramal Pharma Limited’s price movement after its last earnings report?

Piramal Pharma Limited reported an EPS of -₹0.7 in its last earnings report, missing expectations of -₹0.345. Following the earnings report the stock price went up 1.138%.

Which hedge fund is a major shareholder of Piramal Pharma Limited?

Currently, no hedge funds are holding shares in IN:PPLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Piramal Pharma Limited

Piramal Pharma Limited (PPLPHARMA) is a leading global pharmaceutical company based in India, operating under the Piramal Group. The company focuses on developing and manufacturing a wide range of pharmaceutical products, including branded and generic formulations, active pharmaceutical ingredients (APIs), and contract development and manufacturing services (CDMO). PPLPHARMA is committed to providing innovative healthcare solutions across various therapeutic areas such as oncology, cardiovascular, and central nervous system disorders, leveraging its extensive research and development capabilities.

Piramal Pharma Limited (PPLPHARMA) Earnings & Revenues

Historic Earnings Reports

PPLPHARMA Stock 12 Month Forecast

Average Price Target

₹305.00

▲(58.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"186":"₹186","216":"₹216","246":"₹246","276":"₹276","306":"₹306"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹305.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹305.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹305.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[186,216,246,276,306],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.3,207.43076923076924,215.56153846153848,223.6923076923077,231.82307692307694,239.95384615384617,248.0846153846154,256.2153846153846,264.34615384615387,272.4769230769231,280.60769230769233,288.73846153846154,296.86923076923074,{"y":305,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.3,207.43076923076924,215.56153846153848,223.6923076923077,231.82307692307694,239.95384615384617,248.0846153846154,256.2153846153846,264.34615384615387,272.4769230769231,280.60769230769233,288.73846153846154,296.86923076923074,{"y":305,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.3,207.43076923076924,215.56153846153848,223.6923076923077,231.82307692307694,239.95384615384617,248.0846153846154,256.2153846153846,264.34615384615387,272.4769230769231,280.60769230769233,288.73846153846154,296.86923076923074,{"y":305,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":228.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":268.23,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":272.77,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":257.98,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":232.75,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":189.83,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":189.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >